Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04401748 · ClinicalTrials.gov registry record · Phase 3

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

A Phase 3 study of Myelodysplastic Syndrome (MDS), sponsored by AbbVie.

Active
Registry status
Phase 3
Development phase
531
Enrollment target
20
Study locations

NCT04401748 is a Phase 3 study of Myelodysplastic Syndrome (MDS) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 531 participants, above the 62-participant average among 17 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (756% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04401748, a Phase 3 study of Myelodysplastic Syndrome (MDS), is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
531 participants
Enrollment target
20
Study locations

Study Summary

Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death from the disease itself. Symptoms of MDS include fatigue, shortness of breath, unusual paleness due to anemia (low red blood cell count), easy or unusual bruising, and red spots just beneath the skin caused by bleeding. The purpose of this study is to see how safe and effective venetoclax and azacitidine (AZA) combination are when compared to AZA and a placebo (contains no medicine), in participants with newly diagnosed higher-risk MDS. Venetoclax is an investigational drug being developed for the treatment of MDS. The study consists of two treatment arms - In one arm, participants will receive venetoclax and AZA. In another arm, participants will receive AZA and placebo. Adult participants with newly diagnosed higher-risk MDS will be enrolled. Around 500 participants will be enrolled in approximately 220 sites worldwide. Participants in one arm will receive oral doses of venetoclax tablet and intravenous (infusion in the vein) or subcutaneous (given under the skin) AZA solution. Participants in another arm will receive oral doses of placebo tablet and intravenous or subcutaneous AZA solution. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.

Conditions Studied

Myelodysplastic Syndrome (MDS)

Interventions

  • DRUG Venetoclax
  • DRUG Placebo
  • DRUG Azacitidine

Study Locations (20)

Florida

  • Florida Cancer Specialists - Fort Myers /ID# 221319 - Fort Myers
  • Memorial Healthcare System /ID# 222703 - Hollywood
  • Florida Cancer Specialists - North /ID# 221318 - St. Petersburg
  • Florida Cancer Specialists - Panhandle /ID# 221315 - Tallahassee
  • Florida Cancer Specialists - East /ID# 221317 - West Palm Beach

California

  • Duplicate_Providence Medical Foundation /ID# 222633 - Fullerton
  • University of California, Los Angeles /ID# 221760 - Los Angeles
  • Torrance Memorial Physician Network Cancer Care /ID# 222702 - Torrance
  • PIH Health Whittier Hospital /ID# 222647 - Whittier

Illinois

  • Northwestern University Feinberg School of Medicine /ID# 220843 - Chicago
  • Duplicate_Rush University Medical Center /ID# 221007 - Chicago
  • Ingalls Memorial Hosp /ID# 220844 - Harvey
  • Illinois Cancer Care, PC /ID# 220840 - Peoria

Colorado

  • Rocky Mountain Cancer Centers - Boulder /ID# 223723 - Boulder

Connecticut

  • Yale University School of Medicine /ID# 222764 - New Haven

Delaware

  • Helen F. Graham Cancer Center & Research Institute /ID# 223731 - Newark

Idaho

  • St. Luke's Mountain State Tumor Institute /ID# 220838 - Boise

Indiana

  • Duplicate_Parkview Cancer Institute /ID# 223620 - Fort Wayne

Trial Details

FieldValue
Enrollment Target 531 participants
Start Date 2020-09-10
Est. Completion 2026-03
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04401748

The ClinicalTrials.gov registry entry for NCT04401748 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 531 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 17 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (756% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myelodysplastic Syndrome (MDS) appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT04401748 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT04401748 about?

NCT04401748 is a clinical study titled "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome". Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and...

What is the current status of trial NCT04401748?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 531 participants. The study started on 2020-09-10. Estimated completion is 2026-03.

What conditions does trial NCT04401748 study?

This clinical trial studies the following conditions: Myelodysplastic Syndrome (MDS).

What interventions are being tested in trial NCT04401748?

The interventions under investigation include: Venetoclax (DRUG), Placebo (DRUG), Azacitidine (DRUG).

Who is sponsoring clinical trial NCT04401748?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04401748 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelodysplastic Syndrome (MDS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelodysplastic Syndrome (MDS)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.